Skip to main navigation Skip to search Skip to main content

First-in-human application of double-stranded RNA bacteriophage in the treatment of pulmonary Pseudomonas aeruginosa infection

  • Linlin Li
  • , Qiu Zhong
  • , Yunze Zhao
  • , Juan Bao
  • , Bing Liu
  • , Zhuojun Zhong
  • , Jing Wang
  • , Lan Yang
  • , Tingting Zhang
  • , Mengjun Cheng
  • , Nannan Wu
  • , Tongyu Zhu
  • , Shuai Le
  • Fudan University
  • Chongqing Medical University
  • Ltd.
  • The First Affiliated Hospital of Xi’an Jiaotong University

Research output: Contribution to journalArticlepeer-review

28 Scopus citations

Abstract

A double-stranded RNA (dsRNA) phage phiYY is able to kill a pyomelanin-producing Pseudomonas aeruginosa strain, which was isolated from a 40-year-old man with interstitial lung disease (ILD) and chronic lung infection. Phage therapy was used as a last resort for this patient. The three-course nebulized phiYY treatment was used to reduce the bacterial burden and clinical symptoms of the patient. Recurrences of P. aeruginosa infections were observed 1–3 days post phage therapy. The recurrent isolates exhibited distinct antibiotic-susceptibility profiles compared with the original strain yet were still susceptible to phiYY. This assay represents the application of dsRNA phage in the treatment of chronic lung infection, albeit the safety and efficacy of the dsRNA phage require further assessment.

Original languageEnglish
Pages (from-to)862-867
Number of pages6
JournalMicrobial Biotechnology
Volume16
Issue number4
DOIs
StatePublished - Apr 2023
Externally publishedYes

Fingerprint

Dive into the research topics of 'First-in-human application of double-stranded RNA bacteriophage in the treatment of pulmonary Pseudomonas aeruginosa infection'. Together they form a unique fingerprint.

Cite this